Search Results
66 items found for "Sandra L Silberman"
Posts (38)
- Pharmacological Properties and Function of PxOctβ3 Octopamine Receptor in Plutella xylostella (L.)
September 2022 "The diamondback moth (Plutella xylostella) is one of the most destructive lepidopteran pests of cruciferous vegetables, and insights into regulation of its physiological processes contribute towards the development of new pesticides against it. Thus, we investigated the regulatory functions of its β-adrenergic-like octopamine receptor (PxOctβ3). The open reading frame (ORF) of PxOctβ3 was phylogenetically analyzed, and the levels of expression of the receptor mRNA were determined. This ORF was also cloned and expressed in HEK-293 cells. A series of octopamine receptor agonists and antagonists were tested against PxOctβ3. We showed that the receptor is a member of the Octβ3 protein family, and an analysis using quantitative PCR showed that it was expressed at all developmental stages of P. xylostella. Octopamine activated PxOctβ3, resulting in increased levels of intracellular cAMP. Furthermore, the agonists naphazoline, clonidine, 2-phenethylamine, and amitraz activated the PxOctβ3 receptor, and naphazoline was the most effective. Only metoclopramide and mianserin had significant antagonistic effects on PxOctβ3, whereas yohimbine, phentolamine, and chlorpromazine lacked obvious antagonistic effects. The injection of double-stranded RNA in an RNA interference assay indicated that PxOctβ3 regulates development in P. xylostella. This study demonstrated the pharmacological properties and functions of PxOctβ3 in P. xylostella, thus, providing a theoretical basis for the design of pesticides that target octopamine receptors." Read more at the source #DrGPCR #GPCR #IndustryNews
- New structural perspectives in G protein-coupled receptor-mediated Src family kinase activation
Sandra Berndt talk about new structural perspectives in GPCR-mediated Src family kinase activation.
- An overview of the compartmentalized GPCR Signaling: Relevance and Implications
., Hunyady, L., Luttrell, L. M., & Lefkowitz, R. J. (2003). L. (2017). doi.org/10.1007/s11064-016-2026-6 Mendizabal-Zubiaga, J., Melser, S., Bénard, G., Ramos, A., Reguero, L. Z., Wilderman, A., Katakia, T., McCann, T., Yokouchi, H., Zhang, L., Corriden, R., Liu, D., Feigin, M
Other Pages (28)
- Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia
Authors Peter J P Croucher , Maya Ridinger , Pamela S Becker , Tara L Lin , Sandra L Silberman , Eunice
- Cannabinoid compounds to augment L-DOPA treatment in Parkinson's Disease
Contest Committee Sponsors GPCR Retreat Program < Back to schedule Cannabinoid compounds to augment L-DOPA
- Neurotoxicity and accumulation of CPPD quinone at environmentally relevant concentrations in Caenorhabditis elegans
After exposure to 0.01-10 μg/L CPPDQ, obvious body accumulation of CPDDQ was detected. Meanwhile, exposure to CPPDQ (0.01-10 μg/L) decreased head thrash, body bend, and forward turn, and increased Nevertheless, only exposure to 10 μg/L CPPDQ induced neurodegeneration in GABAergic system. Exposure to CPPDQ (0.01-10 μg/L) further decreased expressions of daf-7 encoding TGF-β ligand, jnk-1 Additionally, among examined G protein-coupled receptor (GPCR) genes, exposure to CPPDQ (0.01-10 μg/L)